Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Standard
Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. / Rapp, Carmen; Dettling, Steffen; Liu, Fang; Ull, Anna Theresa; Warta, Rolf; Jungk, Christine; Roesch, Saskia; Mock, Andreas; Sahm, Felix; Schmidt, Melissa; Jungwirth, Gerhard; Zweckberger, Klaus; Lamszus, Katrin; Gousias, Konstaninos; Kessler, Almuth F; Grabe, Niels; Loehr, Mario; Ketter, Ralf; Urbschat, Steffi; Senft, Christian; Westphal, Manfred; Abdollahi, Amir; Debus, Juergen; von Deimling, Andreas; Unterberg, Andreas; Simon, Matthias; Herold-Mende, Christel C.
in: CLIN CANCER RES, Jahrgang 25, Nr. 17, 01.09.2019, S. 5260-5270.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
AU - Rapp, Carmen
AU - Dettling, Steffen
AU - Liu, Fang
AU - Ull, Anna Theresa
AU - Warta, Rolf
AU - Jungk, Christine
AU - Roesch, Saskia
AU - Mock, Andreas
AU - Sahm, Felix
AU - Schmidt, Melissa
AU - Jungwirth, Gerhard
AU - Zweckberger, Klaus
AU - Lamszus, Katrin
AU - Gousias, Konstaninos
AU - Kessler, Almuth F
AU - Grabe, Niels
AU - Loehr, Mario
AU - Ketter, Ralf
AU - Urbschat, Steffi
AU - Senft, Christian
AU - Westphal, Manfred
AU - Abdollahi, Amir
AU - Debus, Juergen
AU - von Deimling, Andreas
AU - Unterberg, Andreas
AU - Simon, Matthias
AU - Herold-Mende, Christel C
N1 - ©2019 American Association for Cancer Research.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - PURPOSE: Clinically aggressive meningiomas (MGMs) are rare but treatment-resistant tumors in need for more effective therapies. Because tumor-infiltrating T lymphocytes (TILs) are essential for successful immunotherapy, we assessed TIL numbers and their activation status in primary (p-) and recurrent (r-) meningiomas and their impact on survival.EXPERIMENTAL DESIGN: Presence of TILs was analyzed in 202 clinically well-annotated cases (n = 123 pMGMs and n = 79 rMGMs) focusing on higher-grade meningiomas [n = 97 World Health Organization (WHO) °II, n = 62 WHO°III]. TILs were quantified by a semiautomated analysis on whole-tissue sections stained by multicolor immunofluorescence for CD3, CD8, FOXP3, and programmed cell death protein 1 (PD-1).RESULTS: Median T-cell infiltration accounted for 0.59% TILs per total cell count. Although there were no significant WHO°-dependent changes regarding helper (CD3+CD8-FOXP3-) and cytotoxic (CD3+CD8+FOXP3-) TILs in pMGMs, higher number of cytotoxic TILs were associated with an improved progression-free survival (PFS) independent of prognostic confounders. rMGMs were characterized by lower numbers of TILs in general, helper, and cytotoxic TILs. The additional analysis of their activation status revealed that a proportion of PD-1+CD8+ TILs within the TIL population was significantly decreased with higher WHO grade and in rMGMs. Furthermore, lower proportions of PD-1+CD8+ TILs were associated with inferior PFS in multivariate analyses, arguing for PD-1 as activation rather than exhaustion marker.CONCLUSIONS: We identified higher numbers of CD3+CD8+FOXP3- TILs and proportions of PD-1-expressing CD3+CD8+FOXP3- TILs as novel biomarkers for better survival. These findings might facilitate the selection of patients who may benefit from immunotherapy and argue in favor of an intervention in primary rather than recurrent tumors.
AB - PURPOSE: Clinically aggressive meningiomas (MGMs) are rare but treatment-resistant tumors in need for more effective therapies. Because tumor-infiltrating T lymphocytes (TILs) are essential for successful immunotherapy, we assessed TIL numbers and their activation status in primary (p-) and recurrent (r-) meningiomas and their impact on survival.EXPERIMENTAL DESIGN: Presence of TILs was analyzed in 202 clinically well-annotated cases (n = 123 pMGMs and n = 79 rMGMs) focusing on higher-grade meningiomas [n = 97 World Health Organization (WHO) °II, n = 62 WHO°III]. TILs were quantified by a semiautomated analysis on whole-tissue sections stained by multicolor immunofluorescence for CD3, CD8, FOXP3, and programmed cell death protein 1 (PD-1).RESULTS: Median T-cell infiltration accounted for 0.59% TILs per total cell count. Although there were no significant WHO°-dependent changes regarding helper (CD3+CD8-FOXP3-) and cytotoxic (CD3+CD8+FOXP3-) TILs in pMGMs, higher number of cytotoxic TILs were associated with an improved progression-free survival (PFS) independent of prognostic confounders. rMGMs were characterized by lower numbers of TILs in general, helper, and cytotoxic TILs. The additional analysis of their activation status revealed that a proportion of PD-1+CD8+ TILs within the TIL population was significantly decreased with higher WHO grade and in rMGMs. Furthermore, lower proportions of PD-1+CD8+ TILs were associated with inferior PFS in multivariate analyses, arguing for PD-1 as activation rather than exhaustion marker.CONCLUSIONS: We identified higher numbers of CD3+CD8+FOXP3- TILs and proportions of PD-1-expressing CD3+CD8+FOXP3- TILs as novel biomarkers for better survival. These findings might facilitate the selection of patients who may benefit from immunotherapy and argue in favor of an intervention in primary rather than recurrent tumors.
U2 - 10.1158/1078-0432.CCR-19-0389
DO - 10.1158/1078-0432.CCR-19-0389
M3 - SCORING: Journal article
C2 - 31227506
VL - 25
SP - 5260
EP - 5270
JO - CLIN CANCER RES
JF - CLIN CANCER RES
SN - 1078-0432
IS - 17
ER -
